

## RESULTS OF RETAIL ENTITLEMENT OFFER

**Melbourne, Australia – 17 March 2026:** [Adherium Limited](#) (ASX:ADR), a global leader in digital respiratory management and developer of the FDA-cleared Hailie® Smartinhaler® platform is pleased to announce the completion of the retail component of its 1-for-1.5 accelerated non-renounceable entitlement offer (**Retail Entitlement Offer**) of new fully paid shares in the Company (**New Shares**) announced on Monday, 16 February 2026.

The institutional placement (**Placement**) and the accelerated institutional component of the Entitlement Offer, together raised approximately \$6.70 million (before costs) (including \$0.34 million that is subject to shareholder approval) as announced to ASX on Wednesday, 18 February 2026.

The Retail Entitlement Offer closed at 5:00pm (Sydney time) on Thursday, 12 March 2026. Under the Retail Entitlement Offer, the Company has received subscriptions for 27,734,391 New Shares to raise approximately \$83,203 (before costs), inclusive of subscriptions under the top-up facility. The Company did not scale back any valid applications under the top-up facility.

The Entitlement Offer consisting of institutional and retail components (**Entitlement Offer**) (excluding the Placement) raised approximately \$5.45 million (before costs).

The Retail Entitlement Offer was not fully subscribed and, as outlined in the Retail Entitlement Offer booklet announced on Monday, 23 February 2026, the Board reserves the right, subject to compliance with the Corporations Act 2001 (Cth), the ASX Listing Rules and all applicable laws, to place any or all of the shortfall shares (**Shortfall Shares**) to one or more investors within three months of the closing date of the Retail Entitlement Offer. Accordingly, 244,391,217 Shortfall Shares may be placed by the Company for up to three months from Thursday, 12 March 2026 at a price no less than the offer price under the Entitlement Offer, being A\$0.003 per New Share.

New Shares under the Retail Entitlement Offer, including the top-up facility, will be allotted on Thursday, 19 March 2026 and are expected to commence trading on a normal settlement basis on Friday, 20 March 2026. New Shares issued under the Retail Entitlement Offer will rank equally with the Company's existing fully paid ordinary shares on issue.

Further information on the Entitlement Offer is set out in the Equity Raising Investor Presentation released to ASX on Monday, 16 February 2026 and the Retail Offer Booklet released to ASX on Monday, 23 February 2026.



## ASX Release

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

**Investor Enquiries**

Adherium Limited  
[investors@adherium.com](mailto:investors@adherium.com)

**Media Enquiries:**

Haley Chartres  
HACK Director  
[haley@hck.digital](mailto:haley@hck.digital)

**About Adherium (ASX: ADR):**

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at [adherium.com](http://adherium.com)